Final Results
Operational Highlights
Significant progress on its drug research programmes including:
nomination of a pre-clinical development candidate from its Chk1 programme
positive in vivo results from its TYK2 programme
Presentations of research data at high profile international scientific and business conferences
Financial Highlights
£252,500 (before expenses) raised through two share placings
Cash at bank and in hand of £511,000 (2011: £871,000)
Loss on ordinary activities (after taxation) £651,000 (2011: £568,000 loss) in line with
expectations and reflecting planned increase in R&D spend
Since the year-end, agreement on a £4m SEDA financing facility from Yorkville Associates (announced 10 September 2012)